3-acetylindole-2-carboxylic acid | 105399-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-acetylindole-2-carboxylic acid
• 英文别名: 3-acetyl-1H-indole-2-carboxylic acid
• CAS: 105399-10-8
• 化学式: C₁₁H₉NO₃
• 分子量: 203.197
• InChiKey: OYPBMIAOTCXDQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  466.2±30.0 °C(Predicted)
• 密度：
  1.392±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-acetylindole-2-carboxylic acid 在 copper chromite 作用下， 以 喹啉 为溶剂， 以74.2%的产率得到3-乙酰吲哚
  参考文献：
  名称：

  Synthetic studies on indoles and related compounds. XII. A simple general method for the C-3 acylation of ethyl indole-2-carboxylates.

  摘要：

  乙基吲哚-2-羧酸酯（1a）及其衍生物在三氟乙酸酐和磷酸（或聚磷酸）的作用下与多种羧酸反应，有效地合成了相应的乙基3-酰基吲哚-2-羧酸酯（3）。然而，强酸性羧酸和含氮羧酸的酰化效果较差。乙基3-酰基吲哚-2-羧酸酯（3）很容易转化为3-酰基吲哚（5）。

  DOI：

  10.1248/cpb.33.4707
• 作为产物：
  描述：

  ethyl 3-acetyl-1H-indole-2-carboxylate 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 以98.1%的产率得到3-acetylindole-2-carboxylic acid
  参考文献：
  名称：

  Synthetic studies on indoles and related compounds. XII. A simple general method for the C-3 acylation of ethyl indole-2-carboxylates.

  摘要：

  乙基吲哚-2-羧酸酯（1a）及其衍生物在三氟乙酸酐和磷酸（或聚磷酸）的作用下与多种羧酸反应，有效地合成了相应的乙基3-酰基吲哚-2-羧酸酯（3）。然而，强酸性羧酸和含氮羧酸的酰化效果较差。乙基3-酰基吲哚-2-羧酸酯（3）很容易转化为3-酰基吲哚（5）。

  DOI：

  10.1248/cpb.33.4707

文献信息

• Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
  申请人：——

  公开号：US20040018986A1

  公开（公告）日：2004-01-29

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性的化合物，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期来发挥作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，用于体外使用或用于治疗HCV感染的患者。本发明还涉及通过给患者施用包含本发明化合物的组合物来治疗患者的HCV感染的方法。此外，本发明还涉及制备这些化合物的方法。
• Synthetic Studies on Indoles and Related Compounds. XXVI. The Debenzylation of Protected Indole Nitrogen with Aluminum Chloride. (2).
  作者：Toshiko WATANABE、Atsushi KOBAYASHI、Michiko NISHIURA、Hiroyuki TAKAHASHI、Tomoko USUI、Izumi KAMIYAMA、Naomi MOCHIZUKI、Kumiko NORITAKE、Yuusaku YOKOYAMA、Yasuoki MURAKAMI

  DOI：10.1248/cpb.39.1152

  日期：——

  A new debenzylation method using aluminum chloride in benzene or anisole, which had been developed by us for N-benzyl-2-acyl- and -2-ethoxycarbonylindoles, was applied to benzyl derivatives of other types of indoles and related compounds. Among them, N-benzyl derivatives of fully aromatized indoles, carbazoles and β-carbolines, and some benzamides were debenzylated successfully, whereas those of oxindoles and heterocyclic amides were not. As to the effect of a p-substituent on the benzyl group, it was found that an electron-donating substituent accelerates deprotection, whereas an electron-attracting substituent delays or prevents deprotection.

  我们针对 N-苄基-2-酰基吲哚和-2-乙氧基羰基吲哚开发了一种在苯或苯甲醚中使用氯化铝的新型脱苄基方法，并将其应用于其他类型吲哚和相关化合物的苄基衍生物。其中，完全芳香化的吲哚、咔唑和 β-咔啉的 N-苄基衍生物以及一些苯甲酰胺被成功地去苄基化，而氧化吲哚和杂环酰胺的 N-苄基衍生物则没有成功去苄基化。至于苄基上的对取代基的影响，研究发现，供电子的取代基会加速脱保护作用，而引电子的取代基则会延迟或阻止脱保护作用。
• Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
  申请人：Cottrell M. Kevin

  公开号：US20050137140A1

  公开（公告）日：2005-06-23

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及化合物I的公式：或其药学上可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期而发挥作用，并且还可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于给患有HCV感染的患者的治疗，以及制备这些化合物的过程。本发明还涉及通过给予含有本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。
• Inhibitors of serine proteases, particular HCV NS3-NS4A protease
  申请人：Pitlik Janos

  公开号：US20070292933A1

  公开（公告）日：2007-12-20

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性的化合物，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期而起作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗患有HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Pitlik Janos

  公开号：US20100173851A1

  公开（公告）日：2010-07-08

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的化合物。因此，它们通过干扰丙型肝炎病毒的生命周期发挥作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患者的HCV感染的方法。本发明还涉及制备这些化合物的方法。